Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK financials should look good but clinic is the focus
07:37am, Friday, 27'th Jan 2023
GSK has done well enough since the Haleon consumer products arm was spun out last year, though after a decent run-up to the end of 2022, shares have gone a bit flat since. Fourth quarter and final res
How Could GSK's RSV Vaccine Change its Valuation?
01:45am, Friday, 27'th Jan 2023
GSK plc (NYSE: GSK) is in the running with Moderna Inc. (NASDAQ: MRNA) and Pfizer (NYSE: PFE) to produce respiratory syncytial virus (RSV) vaccines, and analysts outside the company predict it could h
GSK faces new RSV vaccine competitor after Moderna data, says Barclays
03:55am, Friday, 20'th Jan 2023
GSK is facing a new competitor for its respiratory syncytial virus RSV vaccine after Moderna published data for its alternative, according to analysts at Barclays. “Moderna's efficacy data looks in
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
01:41pm, Thursday, 19'th Jan 2023
Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks. The post Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Crack
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
05:03pm, Tuesday, 17'th Jan 2023
Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84% effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle
GSK growing optimistic on HIV but long term challenges remain - analyst
07:51am, Wednesday, 11'th Jan 2023
GSK PLC (LSE:GSK, NYSE:GSK) is growing at a "robust" rate and showing increasing confidence in its HIV treatments, according to Jefferies analysts, though they cut their share price target due to long
GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference (Transcript)
01:40pm, Tuesday, 10'th Jan 2023
GSK plc (NYSE:GSK ) 41st Annual JPMorgan Healthcare Conference January 10, 2023 10:30 AM ET Company Participants Emma Walmsley - Chief Executive Officer Luke Miels - Chief Commercial Officer David Red
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report?
01:33pm, Monday, 09'th Jan 2023
Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GSK, AstraZeneca: Will the two UK drugs giants ride the US$74bn pharma wave or will they be left beached?
07:54am, Friday, 06'th Jan 2023
The global pharma sector is expected to see clinical trial readouts that could potentially de-risk approximately US$74bn of peak sales in 2023, according to a research report from Credit Suisse, This
GSK Signs Deal to Develop Antibodies for Treating Cancer
02:17pm, Thursday, 05'th Jan 2023
GSK (GSK) partners with WuXi Biologics to develop bi- & multi-specific T-cell engaging antibodies. GSK will have an exclusive license to develop and commercialize these candidates.
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
09:01am, Tuesday, 03'rd Jan 2023
GSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive sales, making up for the lower sales of established drugs due to generic erosion.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
11:36am, Wednesday, 28'th Dec 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023
10:51am, Wednesday, 28'th Dec 2022
Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
12:47pm, Tuesday, 27'th Dec 2022
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR
GSK or TECH: Which Is the Better Value Stock Right Now?
12:47pm, Monday, 26'th Dec 2022
GSK vs. TECH: Which Stock Is the Better Value Option?
